Logo

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma

Share this

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma

Shots:

  • The P-III IMbrave150 study involves assessing Tecentriq (IV- 1200mg) + Avastin (IV- 15mg/kg) vs Sorafenib (400mg- bid) in 501 (194 from China) patients in a ratio (2:1) in patients with unresectable HCC- prior not treated with systemic therapy
  • The Chinese patients demonstrated a 56% improvement in OS- 40% reduction in PFS and is well tolerated with a consistent safety profile
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression

Click here ­to­ read full press release/ article 

 Ref: Roche | Image: Roche 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions